FDA Approved PET Radiopharmaceuticals

Fludeoxyglucose F18 Injection (FDG)

Chemically, it is 2-deoxy-2-(18F)fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule. FDG is taken up by cells, phosphorylated by the enzyme hexokinase and retained by tissues with high glucose metabolic activity such as brain and malignant tumors.


FDG is indicated in PET imaging for the assessment of abnormal malignant tumor glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer.

FDG is indicated in PET imaging in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function.

FDG is indicated in PET imaging in patients for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. It has also been approved for use in diagnosing Alzheimer’s disease (AD).

Ammonia N13 Injection

The active ingredient of Ammonia N13 Injection, [13N]Ammonia, has the molecular formula NH3, and a molecular weight of 16.02. Following intravenous injection and transport into myocardial cells, it is converted to [13N]glutamine mediated by adenosine triphosphate (ATP) and glutamine synthetase.


Ammonia N13 Injection is indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.

Sodium fluoride F18 Injection

The active ingredient of Sodium fluoride F18 injection, is sodium fluoride. It has the molecular formula Na[18F] with a molecular weight of 40.99. Fluoride F 18 ion (F-) normally accumulates in areas of increased osteogenic activity during growth, infection, malignancy (primary or metastatic) following trauma, or inflammation of bone.


Sodium Fluoride F18 Injection is indicated for diagnostic PET imaging of bone to define areas of altered osteogenic activity.

Management Team
Contract Manufacturing of IND Radiopharmaceuticals
Research and Development
Educational Materials
Radionuclide Therapy
Radionuclide Therapy